Prognostic Value of the Neutrophil-to-lymphocyte Ratio, Platelet-to- lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Melanoma Patients: A Cohort Study
DOI:
https://doi.org/10.2340/actadv.v104.27571Keywords:
biomarkers, Neutrophil-to-lymphocyte ratio, melanoma, Platelet-to-lymphocyte ratio, prognosisAbstract
The prognostic value of the neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio in patients with melanoma has yielded controversial results in the literature. A retrospective single-centre cohort study was conducted from 1998 to 2020, including patients diagnosed with invasive melanoma. A total of 2,721 patients were included in the study. The median follow-up was 8.23 years (IQR 4.41–13.25). The median baseline neutrophil- lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio values increased significantly (p < 0.001) with the increasing American Joint Committee on Cancer stage. The optimal cut-off values for neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio were determined as 2.1, 184 and 0.2, respectively. In the multivariate analysis, high levels of neutrophil-lymphocyte ratio (≥ 2.1), platelet-lymphocyte ratio (≥ 184) and monocyte-lymphocyte ratio (≥ 0.2) were independently associated with significantly shorter melanoma-specific survival (neutrophil-lymphocyte ratio: HR 1.30, 95% CI 1.06–1.60, p = 0.013; platelet-lymphocyte ratio: HR 1.37, 95% CI 1.06–1.76, p = 0.014; monocyte- lymphocyte ratio: HR 1.29, 95% CI 1.05–1.58, p = 0.015) and overall survival (neutrophil-lymphocyte ratio: HR 1.39, 95% CI 1.19–1.64, p < 0.001; platelet- lymphocyte ratio: HR 1.44, 95% CI 1.19–1.74, p < 0.001; monocyte-lymphocyte ratio: HR 1.42, 95% CI 1.21–1.66, p < 0.001). High levels of neutrophil- lymphocyte ratio and monocyte-lymphocyte ratio were also associated with poor relapse-free survival, while platelet-lymphocyte ratio was not. In conclusion, baseline neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and monocyte-lymphocyte ratio were identified as independent predictors for the prognosis of melanoma.
Downloads
References
Meheus F, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol 2022; 158: 495-503.
https://doi.org/10.1001/jamadermatol.2022.0160 DOI: https://doi.org/10.1001/jamadermatol.2022.0160
Diakos CI, Charles KA, McMillan DC, Clarke SJ. Cancer-related inflammation and treatment effectiveness. Lancet Oncol 2014; 15: e493-503.
https://doi.org/10.1016/S1470-2045(14)70263-3 DOI: https://doi.org/10.1016/S1470-2045(14)70263-3
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
https://doi.org/10.1038/nature01322 DOI: https://doi.org/10.1038/nature01322
Liu J, Lin PC, Zhou BP. Inflammation fuels tumor progress and metastasis. Curr Pharm Des 2015; 21: 3032-3040.
https://doi.org/10.2174/1381612821666150514105741 DOI: https://doi.org/10.2174/1381612821666150514105741
Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014; 106: dju124.
https://doi.org/10.1093/jnci/dju124 DOI: https://doi.org/10.1093/jnci/dju124
Howard R, Kanetsky PA, Egan KM. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep 2019; 9: 19673.
https://doi.org/10.1038/s41598-019-56218-z DOI: https://doi.org/10.1038/s41598-019-56218-z
Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One 2014; 9: e101119.
https://doi.org/10.1371/journal.pone.0101119 DOI: https://doi.org/10.1371/journal.pone.0101119
Capone M, Giannarelli D, Mallardo D, Madonna G, Festino L, Grimaldi AM, et al. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab. J Immunother Cancer 2018; 6: 74.
https://doi.org/10.1186/s40425-018-0383-1 DOI: https://doi.org/10.1186/s40425-018-0383-1
Ferrucci PF, Ascierto PA, Pigozzo J, Del Vecchio M, Maio M, Antonini Cappellini GC, et al. Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab. Ann Oncol 2016; 27: 732-738.
https://doi.org/10.1093/annonc/mdw016 DOI: https://doi.org/10.1093/annonc/mdw016
Lino-Silva LS, Salcedo-Hernández RA, García-Pérez L, Meneses-García A, Zepeda-Najar C. Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma. Melanoma Res 2017; 27: 140-144.
https://doi.org/10.1097/CMR.0000000000000333 DOI: https://doi.org/10.1097/CMR.0000000000000333
Zhan H, Ma JY, Jian QC. Prognostic significance of pretreatment neutrophil-to-lymphocyte ratio in melanoma patients: a meta-analysis. Clin Chim Acta 2018; 484: 136-140.
https://doi.org/10.1016/j.cca.2018.05.055 DOI: https://doi.org/10.1016/j.cca.2018.05.055
Failing JJ, Yan Y, Porrata LF, Markovic SN. Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients. Melanoma Res 2017; 27: 596-600.
https://doi.org/10.1097/CMR.0000000000000404 DOI: https://doi.org/10.1097/CMR.0000000000000404
Minowa T, Kato J, Hida T, Horimoto K, Sato S, Sawada M, et al. Prognostic role of platelet to lymphocyte and lymphocyte to monocyte ratios in advanced melanoma treated with anti-programmed death-1. Eur J Dermatol 2018; 28: 705-707.
https://doi.org/10.1684/ejd.2018.3381 DOI: https://doi.org/10.1684/ejd.2018.3381
Wade RG, Robinson AV, Lo MCI, Keeble C, Marples M, Dewar DJ, et al. Baseline neutrophil-lymphocyte and platelet-lymphocyte ratios as biomarkers of survival in cutaneous melanoma: a multicenter cohort study. Ann Surg Oncol 2018; 25: 3341-3349.
https://doi.org/10.1245/s10434-018-6660-x DOI: https://doi.org/10.1245/s10434-018-6660-x
Cohen JT, Miner TJ, Vezeridis MP. Is the neutrophil-to-lymphocyte ratio a useful prognostic indicator in melanoma patients? Melanoma Manag 2020; 7: Mmt47.
https://doi.org/10.2217/mmt-2020-0006 DOI: https://doi.org/10.2217/mmt-2020-0006
Podlipnik S, Carrera C, Sánchez M, Arguis P, Olondo ML, Vilana R, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: a prospective cohort study. J Am Acad Dermatol 2016; 75: 516-524.
https://doi.org/10.1016/j.jaad.2016.02.1229 DOI: https://doi.org/10.1016/j.jaad.2016.02.1229
Team RC. R: A Language and Environment for Statistical Computing. Vienna, 2023.
Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-444.
https://doi.org/10.1038/nature07205 DOI: https://doi.org/10.1038/nature07205
Robinson AV, Keeble C, Lo MCI, Thornton O, Peach H, Moncrieff MDS, et al. The neutrophil-lymphocyte ratio and locoregional melanoma: a multicentre cohort study. Cancer Immunol Immunother 2020; 69: 559-568.
https://doi.org/10.1007/s00262-019-02478-7 DOI: https://doi.org/10.1007/s00262-019-02478-7
Shaul ME, Fridlender ZG. Neutrophils as active regulators of the immune system in the tumor microenvironment. J Leukoc Biol 2017; 102: 343-349.
https://doi.org/10.1189/jlb.5MR1216-508R DOI: https://doi.org/10.1189/jlb.5MR1216-508R
Gonzalez H, Hagerling C, Werb Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev 2018; 32: 1267-1284.
https://doi.org/10.1101/gad.314617.118 DOI: https://doi.org/10.1101/gad.314617.118
Fortes C, Mastroeni S, Zappalà AR, Passarelli F, Ricci F, Abeni D, et al. Early inflammatory biomarkers and melanoma survival. Int J Dermatol 2023; 62: 752-758.
https://doi.org/10.1111/ijd.16629 DOI: https://doi.org/10.1111/ijd.16629
Pinto-Paz ME, Cotrina-Concha JM, Benites-Zapata VA. Mortality in cutaneous malignant melanoma and its association with neutrophil-to-lymphocyte ratio. Cancer Treat Res Commun 2021; 29: 100464.
https://doi.org/10.1016/j.ctarc.2021.100464 DOI: https://doi.org/10.1016/j.ctarc.2021.100464
Wagner NB, Luttermann F, Gassenmaier M, Forschner A, Leiter U, Garbe C, et al. Absolute and relative differential blood count predicts survival of AJCC stage I-II melanoma patients scheduled for sentinel lymph node biopsy. Australas J Dermatol 2020; 61: e310-e318.
https://doi.org/10.1111/ajd.13248 DOI: https://doi.org/10.1111/ajd.13248
Davis JL, Langan RC, Panageas KS, Zheng J, Postow MA, Brady MS, et al. Elevated blood neutrophil-to-lymphocyte ratio: a readily available biomarker associated with death due to disease in high risk nonmetastatic melanoma. Ann Surg Oncol 2017; 24: 1989-1996.
https://doi.org/10.1245/s10434-017-5836-0 DOI: https://doi.org/10.1245/s10434-017-5836-0
Rosner S, Kwong E, Shoushtari AN, Friedman CF, Betof AS, Brady MS, et al. Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma. Cancer Med 2018; 7: 690-697.
https://doi.org/10.1002/cam4.1356 DOI: https://doi.org/10.1002/cam4.1356
Cananzi FC, Dalgleish A, Mudan S. Surgical management of intraabdominal metastases from melanoma: role of the neutrophil to lymphocyte ratio as a potential prognostic factor. World J Surg 2014; 38: 1542-1550.
https://doi.org/10.1007/s00268-013-2418-6 DOI: https://doi.org/10.1007/s00268-013-2418-6
Ding Y, Zhang S, Qiao J. Prognostic value of neutrophil-to-lymphocyte ratio in melanoma: evidence from a PRISMA-compliant meta-analysis. Medicine (Baltimore) 2018; 97: e11446.
https://doi.org/10.1097/MD.0000000000011446 DOI: https://doi.org/10.1097/MD.0000000000011446
Ferrucci PF, Gandini S, Battaglia A, Alfieri S, Di Giacomo AM, Giannarelli D, et al. Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients. Br J Cancer 2015; 112: 1904-1910.
https://doi.org/10.1038/bjc.2015.180 DOI: https://doi.org/10.1038/bjc.2015.180
Li Y, Meng Y, Sun H, Ye L, Zeng F, Chen X, et al. The prognostic significance of baseline neutrophil-to-lymphocyte ratio in melanoma patients receiving immunotherapy. J Immunother 2022; 45: 43-50.
https://doi.org/10.1097/CJI.0000000000000392 DOI: https://doi.org/10.1097/CJI.0000000000000392
Cassidy MR, Wolchok RE, Zheng J, Panageas KS, Wolchok JD, Coit D, et al. Neutrophil to lymphocyte ratio is associated with outcome during ipilimumab treatment. EBioMedicine 2017; 18: 56-61.
https://doi.org/10.1016/j.ebiom.2017.03.029 DOI: https://doi.org/10.1016/j.ebiom.2017.03.029
Finon A, Zaragoza J, Maillard H, Beneton N, Bens G, Samimi M, et al. A high neutrophil to lymphocyte ratio prior to BRAF inhibitor treatment is a predictor of poor progression-free survival in patients with metastatic melanoma. Eur J Dermatol 2018; 28: 38-43.
https://doi.org/10.1684/ejd.2017.3167 DOI: https://doi.org/10.1684/ejd.2017.3167
Ma J, Kuzman J, Ray A, Lawson BO, Khong B, Xuan S, et al. Neutrophil-to-lymphocyte ratio (NLR) as a predictor for recurrence in patients with stage III melanoma. Sci Rep 2018; 8: 4044.
https://doi.org/10.1038/s41598-018-22425-3 DOI: https://doi.org/10.1038/s41598-018-22425-3
Wang E, Huang H, Tang L, Tian L, Yang L, Wang S, et al. Prognostic significance of platelet lymphocyte ratio in patients with melanoma: a meta-analysis. Medicine (Baltimore) 2021; 100: e27223.
https://doi.org/10.1097/MD.0000000000027223 DOI: https://doi.org/10.1097/MD.0000000000027223
Qi Y, Zhang Y, Fu X, Wang A, Yang Y, Shang Y, et al. Platelet-to-lymphocyte ratio in peripheral blood: a novel independent prognostic factor in patients with melanoma. Int Immunopharmacol 2018; 56: 143-147.
https://doi.org/10.1016/j.intimp.2018.01.019 DOI: https://doi.org/10.1016/j.intimp.2018.01.019
Zhang F, Gong W. Prognostic value of the platelet-to-lymphocyte ratio in patients with melanoma: a meta-analysis. Front Oncol 2020; 10: 1116.
https://doi.org/10.3389/fonc.2020.01116 DOI: https://doi.org/10.3389/fonc.2020.01116
Han SN, Feng SJ, Liu Y. Prognostic and clinicopathological significance of the platelet-to-lymphocyte ratio in melanoma: a meta-analysis involving 2099 patients. Kaohsiung J Med Sci 2021; 37: 55-62.
https://doi.org/10.1002/kjm2.12290 DOI: https://doi.org/10.1002/kjm2.12290
Gandini S, Ferrucci PF, Botteri E, Tosti G, Barberis M, Pala L, et al. Prognostic significance of hematological profiles in melanoma patients. Int J Cancer 2016; 139: 1618-1625.
https://doi.org/10.1002/ijc.30215 DOI: https://doi.org/10.1002/ijc.30215
Iacono D, Basile D, Gerratana L, Vitale MG, Pelizzari G, Cinausero M, et al. Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma. Melanoma Res 2019; 29: 510-515.
https://doi.org/10.1097/CMR.0000000000000584 DOI: https://doi.org/10.1097/CMR.0000000000000584
Chen Y, Wang W, Zeng L, Mi K, Li N, Shi J, et al. Association between neutrophil-lymphocyte ratio and all-cause mortality and cause-specific mortality in US adults, 1999-2014. Int J Gen Med 2021; 14: 10203-10211.
https://doi.org/10.2147/IJGM.S339378 DOI: https://doi.org/10.2147/IJGM.S339378
Published
How to Cite
License
Copyright (c) 2024 Sümeyre Seda Ertekin, Cristina Mangas, Constanza Riquelme-Mc Loughlin, Cristina Carrera, Josep Malvehy , Susana Puig, Sebastian Podlipnik
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
